David King - LIFE Old Senior Vice President - Research

President

Dr. David John King, Ph.D., is no longer Senior Vice President Research of the Company, effective as of December 31, 2018. Dr. King has served as our Senior Vice President, Research since September 2016. Davids industry experience is highlighted by his tenures at Medarex, Inc. and Celltech Therapeutics Ltd. . At Medarex, he led programs to identify therapeutic antibodies and played a key role in programs targeting novel biologics, and at Celltech, he directed the protein biochemistry and antibody engineering activities that led to the discovery and development of Cimzia . After Medarex, Dr. King served as Chief Scientific Officer at AnaptysBio, Inc. from November 2008 to February 2016 where he led research that developed a novel technology for generating antibody therapeutics, which was successfully used to generate innovative clinical candidates for a number of pharmaceutical partnerships and for internal development. Most recently, Dr. King served as Senior Vice President of Research at Tunitas Therapeutics, where he led the companys research and preclinical activities from February 2016 to September 2016 since 2018.
Age 65
Tenure 7 years
Professional MarksPh.D
Phone858 731 8389
Webhttps://www.atyrpharma.com
King received his B.S. from the University of Warwick and his Ph.D. from the University of Surrey, both in the United Kingdom, and was a Glaxo Group Research postdoctoral fellow.

David King Latest Insider Activity

Tracking and analyzing the buying and selling activities of David King against LIFE Old stock is an integral part of due diligence when investing in LIFE Old. David King insider activity provides valuable insight into whether LIFE Old is net buyers or sellers over its current business cycle. Note, LIFE Old insiders must abide by specific rules, including filing SEC forms every time they buy or sell LIFE Old'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

LIFE Old Management Efficiency

The company has return on total asset (ROA) of (0.2937) % which means that it has lost $0.2937 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5561) %, meaning that it created substantial loss on money invested by shareholders. LIFE Old's management efficiency ratios could be used to measure how well LIFE Old manages its routine affairs as well as how well it operates its assets and liabilities.
LIFE Old currently holds 15.1 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. LIFE Old has a current ratio of 9.88, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about LIFE Old's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 3 records

PRESIDENT Age

Kelly CarranzaAcumen Pharmaceuticals
N/A
Erin MDTerns Pharmaceuticals
53
James DohertyAcumen Pharmaceuticals
57
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company was incorporated in 2005 and is headquartered in San Diego, California. Atyr Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 49 people. LIFE Old (LIFE) is traded on NASDAQ Exchange in USA and employs 56 people.

Management Performance

LIFE Old Leadership Team

Elected by the shareholders, the LIFE Old's board of directors comprises two types of representatives: LIFE Old inside directors who are chosen from within the company, and outside directors, selected externally and held independent of LIFE. The board's role is to monitor LIFE Old's management team and ensure that shareholders' interests are well served. LIFE Old's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, LIFE Old's outside directors are responsible for providing unbiased perspectives on the board's policies.
Danielle Campbell, VP Resource
Melissa Ashlock, Vice President - External Scientific Alliances and Human Genetics
MS MD, CEO President
XiangLei Yang, Founder
Ying Buechler, Executive Manufacturing
Jill Broadfoot, Chief Officer
David King, Senior Vice President - Research
Ashlee Dunston, Director Communications
Peter Villiger, Vice Development
Leslie Nangle, Vice Research
Nancy Krueger, General Secretary

LIFE Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is LIFE Old a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.
You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.

Other Consideration for investing in LIFE Stock

If you are still planning to invest in LIFE Old check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the LIFE Old's history and understand the potential risks before investing.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities